All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How might the MASS score aid treatment decisions for newly diagnosed patients?

Featured
May 27, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in newly diagnosed MM.

Shaji Kumar, Mayo Clinic, Rochester, US, spoke with the Multiple Myeloma Hub about his recent paper “A simple additive staging system for newly diagnosed multiple myeloma” published in Blood Cancer Journal.

With reference to this paper, we asked, How might the MAYO Additive Staging System (MASS) score aid treatment decisions for newly diagnosed patients?

How might the MASS score aid treatment decisions for newly diagnosed patients?

Kumar begins his answer by describing the current situation regarding risk stratification in the field of multiple myeloma, including the role of the Revised International Staging System (R-ISS) and the importance of the inclusion of cytogenetic abnormalities, such chromosome 1q gain/amplification.

Kumar speaks on the creation of the MASS score using the ISS Stage III (serum β2-microglobulin ≥5.5 mg/L) and the other risk factors shown in Figure 1. Following on from this, the potential benefits of this scoring system are summarized.

Figure 1. MASS*

IGH, immunoglobulin heavy chain locus; ISS, International Staging System; LDH, lactate dehydrogenase; MASS, Mayo Additive Staging System; OS, overall survival; PFS, progression-free survival.
*Adapted from Abdallah, et al.1

  1. Abdallah NH, Binder M, Rajkumar SV, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12(1):21, DOI: 1038/s41408-022-00611-x

Share:

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox